(Oslo, 14th of September 2026) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarters in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery, announces the an extraordinary General Meeting for the company.
The extraordinary General Meeting will take place on the 5th of October 2026 at
10.00 and is held at Medistim's offices at Økernveien 94 in Oslo. Attached are
the agenda for the meeting and the voting form. Shareholders will receive a
separate letter including reference and pin code to register votes. It is
possible to give proxy with and without voting instructions. By using a proxy
with voting instructions, the shareholders will vote on the specific issues
without personal attendance. For further information on the use of proxy and
voting,see general information at the bottom of the notice and enclosed proxy
forms.
About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment, and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK,
Spain, Denmark, Sweden, Japan and Norway,in addition to the about 60
distributors in Europe, Asia, Middle East, Africa, Canada and South America.
For more information, visit the Medistim home page: www.Medistim.com. This
information is subject to the disclosure requirements pursuant to section 5-12
of the Norwegian Securities Trading Act (Verdipapirhandelloven).
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com
ASA\
Tel: + 47 906 59 940\
Email: thomas.jakobsen@medistim.com\